Nanoscope Therapeutics appoints Glenn Sblendorio as Chairman of the Board


Sblendorio brings decades of experience in the ophthalmic industry to his position on the Nanoscope board as the company continues to move forward in their commitment to retinal diseases.

©xy -

Image credit: ©xy -

Nanoscope Therapeutics has appointed Glenn Sblendorio as Chairman of the Board. Sblendorio has more than 30 years of experience marked by extensive executive leadership in the ophthalmic industry and will support Nanoscope in reaching its strategic vision.1

Sblendorio is set to play a pivotal role in ensuring the effectiveness of the board of directors in implementing Nanoscope's organizational strategy and direction. His comprehensive understanding of finance and business development will help to guide Nanoscope through its mission of bringing hope for renewed sight to those affected by retinal degenerative diseases.1

In the company’s press release1, Sblendorio noted his hopes and excitement for the future of his and the company’s roles, saying, "I am honored to join Nanoscope as Chairman of the Board. The company's commitment to advancing novel treatments for retinal degenerative diseases aligns with my passion for making a meaningful impact in the retina space. I look forward to working collaboratively with the board and leadership team to drive innovation and contribute to the realization of our shared mission."

Sblendorio held various key leadership roles at IVERIC bio, Inc., an Astellas Company (formerly Ophthotech Corporation), including CEO, President, and Director. He also served as EVP, COO, CFO and Treasurer. Additionally, he served as President, CFO and Director at The Medicines Company and as EVP and CFO at Eyetech Pharmaceuticals. Earlier in his career, Mr. Sblendorio was a Managing Director at MPM Capital Advisors, LLC, and held various senior financial positions at Hoffman-La Roche.1

Nanoscope CEO and Co-Founder Sulagna Bhattacharya shared the company’s enthusiasm for this appointment, saying, "We are elated to welcome Glenn Sblendorio as our Chairman of the Board. His wealth of experience in building and scaling progressive companies, coupled with his thorough knowledge of successfully bringing retinal treatments to market, will undoubtedly strengthen Nanoscope's position as a leader in the ophthalmic industry. We look forward to leveraging his expertise as we navigate the next phases of our development."1

The company also noted that Sblendorio’s appointment reflects Nanoscope’s forward movement in ophthalmology and all that is to come from their research.

  1. Nanoscope Therapeutics Continues Leadership Growth; Welcomes Accomplished Finance and Biotech Leader Glenn Sblendorio as Chairman of the Board. Nanoscope Therapeutics. December 4, 2023. Accessed December 11, 2023.
Related Videos
© 2024 MJH Life Sciences

All rights reserved.